Lebrikizumab is a monoclonal antibody that binds to IL-13 to block the formation of the IL-13Rα1/IL-4Rα heterodimer complex and inhibit the action of IL-13, which plays a key role in AD. Here, IL13 is linked to Alzheimer disease.